Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Piperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.65 |
| ▸ | HTR3B | O95264 | 1/20 | 0.65 |
| ▸ | HTR3A | P46098 | 1/20 | 0.65 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.65 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.65 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.57 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.56 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.55 |
| ▸ | WNT3A | P56704 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperidine SCHEMBL8707735 | 0.92 | HTR3E (0.60) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL64182 | 0.91 | GPR84 (0.77) | GPR84ALDH1A1PBRM1ATMNPC1 | |
| Hydrochloric Acid SCHEMBL28246505 | 0.89 | GPR84 (0.74) | GPR84ALDH1A1PBRM1ATMNPC1 | |
| SCHEMBL29272694 | 0.89 | GPR84 (0.74) | GPR84ALDH1A1PBRM1ATMNPC1 | |
| SCHEMBL27656464 | 0.89 | GPR84 (0.74) | GPR84ALDH1A1PBRM1ATMNPC1 | |
| Hydrochloric Acid SCHEMBL29435427 | 0.89 | GPR84 (0.74) | GPR84ALDH1A1PBRM1ATMNPC1 | |
| Hydrochloric Acid SCHEMBL7437913 | 0.89 | GPR84 (0.74) | GPR84ALDH1A1PBRM1ATMNPC1 | |
| Ammonia Solution, Strong SCHEMBL27380523 | 0.89 | GPR84 (0.74) | GPR84ALDH1A1PBRM1ATMNPC1 | |
| SCHEMBL27837528 | 0.89 | GPR84 (0.74) | GPR84ALDH1A1PBRM1ATMNPC1 | |
| Hydrochloric Acid SCHEMBL72812 | 0.89 | GPR84 (0.74) | GPR84ALDH1A1PBRM1ATMNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073699-A1 | Compounds and methods to treat cardiac failure and other disorders | SCIOS, INC. | 2003-04-17 | — | — | US | disclosed |
| US-6130235-A | PIPERIDINE MOIETIES COUPLED TO INDOLE, BENZIMIDAZOLE OR BENZOTRIAZOLE. | SCIOS INC. (US) | 2000-10-10 | — | — | US | disclosed |
| EP-0922042-A1 | NOVEL PIPERAZINE CONTAINING COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-06-16 | — | — | EP | disclosed |
| WO-1998006715-A1 | NOVEL PIPERAZINE CONTAINING COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073699-A1 | Compounds and methods to treat cardiac failure and other disorders | RCOR1, NR3C2, CNR1 | HTR3E 397/4885HTR3B 216/4885HTR3A 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.